Octreotide acetate is the current primary treatment for patients with acromegaly, together with other somatostatin analogue, Lanreotide.
Octreotide Acetate is a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide inhibits the secretion of growth hormone, which in turn stops the hormonal sequence in the body that leads to the enlargement of organs.
An oral delayed-release formulation of Octreotide was recently launched in the US. Our API is suitable for both injectable and oral grades.